Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOTHER: EXL01 in advanced HCC
NCT06551272Phase 2Recruiting
- Sponsor
- Centre Eugène Marquis
- Start
- Mar 2025
- Primary completion
- Mar 2026
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
A Phase 2 trial of exl01 in hepatocellular carcinoma (HCC), sponsored by Centre Eugène Marquis. Started Mar 2025; status: recruiting.
02
Drugs
exl01
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06551272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06551272.